Genentech Can't Follow Up Rituxan Alone: Arbitrators
An arbitration panel has ordered Genentech Inc. to stop its work on three follow-up drugs to Rituxan, a popular cancer and arthritis drug it developed through a partnership with Biogen Idec,...To view the full article, register now.
Already a subscriber? Click here to view full article